Our Partners
Medalytix works with a world-class, multi-disciplinary group of partners to bring to market products that can benefit healthcare services globally. We are actively participating in research to deliver automated screening for the main complications of diabetes, allowing simple and rapid identification of potential health problems and thus timely clinical intervention.
University of Aberdeen and Grampian Health Board – since 1990, the University of Aberdeen and NHS Grampian’s Ophthalmic Imaging Group, a multidisciplinary team led by Professor Peter Sharp and Dr John Olson, have been addressing the issue of automated detection of diabetic eye disease and the team has published widely in the field. Their research has led to the development of safe, robust and effective, validated retinal screening software which we now offer to the clinical community.
Professor Peter Sharp
Head of Bio-medical Physics and Bio-Engineering, University of Aberdeen
Dr John Olson
Consultant Ophthalmic Physician and Diabetes Retinal Screening Service Clinical Director (NHS Grampian).
License and collaboration agreements provide Medalytix with exclusive rights to the intellectual property already in existence and also to inventions that arise from the work funded by the company in Aberdeen. The technology is sub-licensed from Scottish Health Innovations Ltd.
Scottish Health Innovations (SHIL) is the not-for-profit company formed with the sole aim of developing ideas and providing technology transfer expertise for the employees within NHS Scotland.
Centre for Eye Research Australia (CERA) conducts research into the leading causes of blindness. It is affiliated with the University of Melbourne and is located at the Royal Victorian Eye and Ear Hospital. Medalytix has exclusive, worldwide rights to intellectual property developed by Professor T Wong and his team at CERA relating to the prediction of cardiovascular disease risk using retinal features.
Future partners
Our story is one of partnership and innovation in automation.
Naturally, any new technology is subject to rigorous validation work and live comparison to human review prior to its integration into any clinical service.
In our search for improved efficiency and quality, we are actively seeking to license proprietary algorithms which have been developed to interrogate digital images. We would be happy to work with interested parties to validate these technologies against large, diverse clinical datasets.
Please contact us at info@medalytix.com for further information.
Our Vision
Our philosophy is one of openness and integrity – delivering proven technology that can help prevent blindness.
Our Team
Medalytix was incorporated in 2005 by a team of experienced healthcare and IT professionals.
About Us
Medalytix was established in 2006, but the chain of events that led to our inception leads back much further.